Keywords: Shire, Velaglucerase, Genzyme, Eliglustat, Gauchers disease, Research

Shire presents strong Ph III velaglucerase alfa data in Type 1 Gaucher disease and Genzyme Ph II with eliglustat at LDN meeting

Article | 12 February 2010

Print This

UK biopharmaceutical company Shire has presented positive results from its first Phase III study (TKT032) evaluating safety and efficacy of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in